2019
DOI: 10.7717/peerj.6228
|View full text |Cite
|
Sign up to set email alerts
|

Label-free quantitative proteomic analysis reveals potential biomarkers for early healing in cutaneous leishmaniasis

Abstract: BackgroundLeishmaniasis is a parasitic disease caused by more than 20 species of the Leishmania genus. The disease is globally distributed and is endemic in 97 countries and three territories in the tropical and subtropical regions. The efficacy of the current treatments is becoming increasingly low either due to incomplete treatment or resistant parasites. Failure of treatment is frequent, and therefore, the search for early biomarkers of therapeutic response in cutaneous leishmaniasis (CL) is urgently needed… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 45 publications
0
7
0
Order By: Relevance
“…The delay in disease development observed in the 10 5 group suggests that anti-leishmanial immune mechanisms were initially triggered but were not sufficient to overwhelm the parasite burden. Other lesion analysis tools, such as changes in the proteomic spectral signature recently described for the L. braziliensis CL in humans, will extend our understanding of skin lesion development ( 54 ). Herein an up-regulation of almost all investigated cytokines was observed during the chronic phase.…”
Section: Discussionmentioning
confidence: 99%
“…The delay in disease development observed in the 10 5 group suggests that anti-leishmanial immune mechanisms were initially triggered but were not sufficient to overwhelm the parasite burden. Other lesion analysis tools, such as changes in the proteomic spectral signature recently described for the L. braziliensis CL in humans, will extend our understanding of skin lesion development ( 54 ). Herein an up-regulation of almost all investigated cytokines was observed during the chronic phase.…”
Section: Discussionmentioning
confidence: 99%
“…of differentially regulated proteins Year References Study No. Up Down Proteins of Homo sapiens Infection based studies L. donovani 2DE; 2D-DIGE; MALDI-TOF/TOF MS/MS; Western blot; ELISA VL vs endemic control VL vs non-endemic control 38 10 2014 [ 35 ] 1 L. braziliensis 2DE-MALDI-TOF/TOF MS CL vs normal skin 9 4 2015 [ 38 ] 2 L. panamensis SDS-PAGE; LC ESI–MS/MS Start of treatment day vs 7th day of treatment 7 5 2019 [ 37 ] 3 Proteins of Mus Musculus Infection based studies L . amazonensis and L .…”
Section: Differentially Modulated Proteins In the Host After mentioning
confidence: 99%
“…Since glycoproteins are the preferred markers for diagnosing diseases [ 36 ], differentially expressed glycoproteins from the Bag et al [ 35 ] study can be used as prognostic and diagnostic markers for VL. Two differential protein expression studies [ 37 , 38 ], involving human subjects with CL, were reported. Da Silva Santos et al [ 38 ] compared the proteome of L. braziliensis infected skin lesion against normal skin biopsy and reported 13 DMP.…”
Section: Differentially Modulated Proteins In the Host After mentioning
confidence: 99%
See 1 more Smart Citation
“…Due to its straightforward method development for a wide variety of candidate analytes, LC-MS can often represent a more precise alternative to immunobinding assays and biomarker panel analyses in the field of targeted proteomics (Himmelsbach, 2012;Rauh, 2012). The use of unlabeled protein profiles to examine differentially expressed proteins in urine samples largely eliminates the variations and biases in replicate MS measurements (Atrih et al, 2014;Montoya et al, 2019).…”
Section: Introductionmentioning
confidence: 99%